The European Court of Justice, the European Union’s highest court, backed a fine issued to AstraZeneca after the pharmaceutical company was found to have hampered competition by blocking rivals from its ulcer drug Losec and selling it for less money. The fine is a validation of the General Court’s, Europe’s second-highest court, 2010 decision to support the European Commission’s finding that AstraZeneca had breached competition law, but is also supportive of of the General Court’s decision to lower the fine originally administered by the Commission of €60 million to €52.5 million.
Featured News
States Vow to Continue Antitrust Fight Against Live Nation Despite DOJ Settlement
Mar 9, 2026 by
CPI
White House Cybersecurity Plan Calls on Private Sector to Partner on US Operations
Mar 9, 2026 by
CPI
Big Tech Data Centers Become Wartime Targets After Drone Strikes on Amazon Sites
Mar 9, 2026 by
CPI
Anthropic Sues Pentagon to Block National Security Blacklist Over AI Restrictions
Mar 9, 2026 by
CPI
A $300 Billion Crypto Market Is Propping Up US Government Debt
Mar 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece